A randomized, double-blind, phase IIa dose-finding study of vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 4, 2008, Pages 386-393

  Kiura, Katsuyuki ^a,k   Nakagawa, Kazuhiko ^b   Shinkai, Tetsu ^c   Eguchi, Kenji ^d   Ohe, Yuichiro ^e   Yamamoto, Nobuyuki ^f   Tsuboi, Masahiro ^g   Yokota, Soichiro ^h   Seto, Takashi ⁱ   Jiang, Haiyi ^j   Nishio, Kazuto ^b   Saijo, Nagahiro ^d   Fukuoka, Masahiro ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^d TOKAI UNIVERSITY HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f SHIZUOKA CANCER CENTER   (Japan)

^g TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^h TONEYAMA NATIONAL HOSPITAL   (Japan)

ⁱ NATIONAL KYUSHU CANCER CENTER   (Japan)

^j ASTRAZENECA   (United Kingdom)

^k NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

more..

Author keywords

EGFR; Non small cell lung cancer; Vandetanib; VEGFR

Indexed keywords

BIOLOGICAL MARKER; VANDETANIB;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DNA SEQUENCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; FEMALE; GENE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HYPERTENSION; JAPAN; JAPANESE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RASH; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 41749097667     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318168d228     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
3. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
4. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
5. Ciardiello F, Troiani T, Bianco R, et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 2006;17:vii109-vii114.
6. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001;61:5090-101.
7. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:2544-55.
8. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-55.
9. Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett 2004;204:197-211.
10. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGFReceptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16:1391-7.
11. Tamura T, Minami H, Yamada Y, et al. A Phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006;1:1002-9.
12. Natale RB, Bodkin D, Govindan R, et al. ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized Phase II trial. Proc Am Soc Clin Oncol 2006;abst 7000.
13. Heymach J, Paz-Ares L, de Braud F, et al. Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(Suppl 18):abst 7544.
14. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007;25:4270-7.
15. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-55.
16. Horiike A, Kimura H, Nishio K, et al. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest 2007;131:1628-34.
17. Gatzemeier U, Blumenschein G, Fosella F, et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. Proc Am Soc Clin Oncol 2006;24:abst 7002.
18. Socinski MA, Novello S, Sanchez JM, et al. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. Proc Am Soc Clin Oncol 2006;24:abst 7001.
19. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37.
20. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91.
21. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
22. Pao W, Miller V, Zakowski M, et al. EGFReceptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11.
23. Hirsch F, Varella-Garcia M, Cappuzzo F, et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007;18:752-60.
24. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
25. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005;23:3227-34.
26. Yoshimoto A, Kasahara K, Nishio M, et al. Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer. Jpn J Clin Oncol 2005;35:233-8.